Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - ADVENTRX Pharmaceuticals, Inc. (ANX-NYSE Amex) |
|
|
“ADVENTRX stands out among its small cap peers because we expect to submit an NDA, the final regulatory hurdle to drug approval, this year. There is only a limited amount of work remaining before we submit that NDA, and we have both the financial and human capital to get there.” - Brian M. Culley, M.A., M.B.A. (ANX) (Interview published June 18, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
ADVENTRX Pharmaceuticals to Present at the
Lippert/Heilshorn Life Sciences & MedTech Virtual Conference on July
20
SAN DIEGO, July 15, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-line Forum on July 20, 2010 at 10:00 a.m. Eastern time. Interested parties can access a live audio webcast with slide presentation at http://www.adventrx.com/, or from the PrecisionIR site at http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=160292. An archived presentation will be available for 30 days. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at http://www.adventrx.com/. SOURCE ADVENTRX Pharmaceuticals, Inc.
|
|
